"Eli Lilly urged the Court to affirm the Federal Circuit's decision and to make it explicitly clear that 'claims like Amgen's-limited solely by functional results with no structural limitations whatsoever- are invalid under § 112.'"Late last week, a slew of additional amicus briefs were filed with the U.S. Supreme Court in Amgen v. Sanofi, a closely-watched case that will consider the scope of the enablement inquiry under 35 U.S.C. § 112.
#development #competition #specifically #supreme-court #preparation #astrazeneca #association #determination #contribution #public-interest
[
add
]
[
|
|
...
]